Wegovy before and after 2 months: what clinical evidence tells us

What the STEP 1 trial data show at the eight-week point

The most rigorous picture of early Wegovy results comes from the STEP 1 trial, published in the New England Journal of Medicine, which followed 1,961 adults with obesity over 68 weeks. The headline figure (roughly 15% average body weight reduction at 68 weeks on 2.4mg semaglutide) is the one quoted most often, but two months in, participants were nowhere near that outcome.

At eight weeks, the majority were on either 0.25mg or 0.5mg weekly. Average weight loss at this stage fell in the range of 3–5% of starting body weight. For someone beginning at 100kg, that is roughly 3–5kg. Meaningful, but a fraction of what accumulated over the full trial period.

This is not a sign that the medicine is not working. The titration schedule exists specifically to let the body adjust and to limit early side effects, particularly nausea. The weeks before reaching the maintenance dose are doing important groundwork. Progress at two months tells you something about tolerability and early response; it does not predict your final outcome.

If you want a fuller picture of how results develop month by month, our page on Wegovy results at three months covers the next stage of the evidence in the same way.

Why two months rarely reflects the medicine's full effect

The standard titration pathway for Wegovy starts at 0.25mg, steps to 0.5mg at week five, then 1mg at week nine, 1.7mg at week thirteen, and reaches the 2.4mg maintenance dose at week seventeen. Two months (eight weeks) sits squarely in the early adjustment window, before the dose driving the most significant appetite suppression is even established.

This matters when reading accounts of two-month results online. Someone reporting 2kg lost at this stage and someone reporting 8kg lost may both be responding normally; individual variation in early response is wide. Starting weight, diet adherence, activity level, and how each person tolerates dose increases all affect the number on the scale at week eight.

The NHS semaglutide medicines page notes that weight loss typically builds gradually over the course of treatment. Our own page on how long Wegovy takes to work covers the full timeline in more detail, including when most people notice appetite changes versus measurable weight change.

One practical note: the timing of your first prescription matters more than people realise. Starting treatment after a holiday, or midway through a month when routine is disrupted, can affect those early weeks. Many people find a Monday start (when the working week's routine kicks in) makes the adjustment period easier to manage.

Side effects in the first two months and what to expect

Early weeks are when gastrointestinal side effects are most common. Nausea is the most frequently reported; constipation, loose stools, bloating, and occasional vomiting also appear in the trial data. In STEP 1, these were most pronounced at dose increases and generally eased within a week or two of settling at each new level.

The NHS England guidance on weight management injections recommends eating smaller portions, avoiding high-fat meals, and staying well hydrated during this phase. If symptoms are severe or persistent, the prescriber may recommend holding the current dose for longer before increasing — this is clinical decision-making, not a failure of the medicine.

For context on how the oral form compares during early treatment, the semaglutide before and after two months page covers the broader picture across both injection and tablet formulations.

It is worth knowing that some side effects (injection-site reactions, occasional headaches, fatigue) are also more noticeable early on and typically reduce over time. Anyone experiencing severe, persistent abdominal pain radiating to the back should seek medical attention promptly and report any unexpected symptoms at the MHRA Yellow Card service.

What two months can tell you, and what to do with it

Two months gives a prescriber two useful data points: tolerability (how the body is handling dose escalation) and early directional response. Neither is definitive. A slow start at two months does not predict poor long-term outcomes; nor does an encouraging early loss guarantee the full trajectory.

For people wondering whether they are on the right treatment, the comparison at later stages is more informative. Our page covering Wegovy results at six months looks at evidence from a point much closer to the maintenance dose, when differences between individuals and between medicines become more meaningful. For those curious about the changes that typically occur between these milestones, our page on what Wegovy results look like at four months bridges the gap with a closer look at progress during that middle phase.

Wegovy is a prescription-only medicine. The decision about whether to continue, adjust the titration, or consider an alternative rests with a clinician who knows your full medical picture. If you are considering starting treatment or have questions about how things are progressing, a prescriber-led consultation is the right starting point. You can find more about our Wegovy treatment overview or explore all weight-loss treatment options through a free consultation with our team.